Blog

  • Egg-eating worms could be the secret to saving Chesapeake Bay’s blue crabs

    Egg-eating worms could be the secret to saving Chesapeake Bay’s blue crabs

    Parasitic, egg-eating worms might sound like the stuff of nightmares, but they’re simply a fact of life for blue crabs in the Chesapeake Bay. Interestingly, a new study published in the journal PLOS One by researchers at William & Mary’s Batten School & VIMS suggests these worms could serve as a valuable biomarker for managing the fishery.

    The most recent Winter Dredge Survey, conducted by the Batten School of Coastal & Marine Sciences & VIMS in collaboration with Maryland’s Department of Natural Resources, recorded historically low numbers of blue crabs in the Chesapeake Bay. The findings have sparked concern among the fishery’s many stakeholders and highlight a need for new tools that can help balance economic and ecological priorities — this study may help with that.

    The worm, Carcinonemertes carcinophila, infests and lives on the egg clutches of female blue crabs. While they do not eat enough eggs to drastically reduce the crabs’ reproductive output, they grow and change color after feeding making them a potential biomarker for determining whether a female crab has spawned. However, crabs living throughout the Chesapeake Bay experience a wide range of salinity levels, and it was previously unclear whether the worms could survive in the lower salinities found in some parts of the Bay and its tributaries.

    “Other species of Carcinonemertes cannot survive in salinity levels below 20 parts per thousand, which is a common occurrence in the Bay’s tributaries and during high-precipitation events,” said Professor Jeffrey Shields at the Batten School & VIMS. “We found this worm to be much tougher than other species.”

    Evaluating the worms’ potential as biomarkers

    The study continues research initiated by former Batten School & VIMS student Alex Schneider Ph.D. ’24, who investigated blue crab reproduction to support improved fishery management. One part of her dissertation focused on Carcinonemertes carcinophila‘s potential for determining the number of times a female crab has reproduced.

    Schneider collaborated with Alex Pomroy, an undergraduate student at William & Mary and the study’s lead author. Under Shields’ mentorship, the researchers collected worms from blue crabs and subjected them to a wide range of salinities.

    As expected, the worms thrived in mid-to-high salinity levels of 20-30 parts per thousand (psu). However, the researchers also found that the worms could acclimate and survive at a salinity of 10 psu and even withstand and recover from short durations (up to 39 hours) at levels as low as five psu.

    “Female crabs often migrate from low-salinity waters to high-salinity waters to lay eggs. We found that the worms had a wide salinity tolerance, and that they survived well at the lower salinities representative of where crabs might begin their migrations,” said Pomroy. “This means that the worms are likely to infest crabs throughout their adult lives, confirming their potential as biomarkers for reproduction.”

    Implications for fishery management

    The blue crab is one of the most important commercial and recreational species in Chesapeake Bay. Egg production is a key component of many fishery models, but it has been difficult to determine how many times a female crab has spawned.

    Female crabs that have not yet produced offspring are termed primiparous, while those that have reproduced multiple times are multiparous. Previous research by Schneider and others at the Batten School & VIMS demonstrated that female blue crabs produce more offspring in their first clutch, with fecundity — or reproductive potential — declining in subsequent clutches. The study also showed that nearly all crabs reproducing in June were primiparous, while those reproducing later in the spawning season were mostly multiparous.

    In another study published in the journal Marine Ecology Progress Series, Schneider and co-authors used the worm to provide the first-ever estimate of the proportion of crabs that have and have not spawned during winter. This information helps managers understand the impacts of commercial and recreational harvest on spawning demographics and the overall composition of the population before the spawning season.

    “If you’re trying to increase the blue crab population in the Bay, it makes sense to protect the primiparous crabs if they are producing more offspring,” said Schneider. “The presence and physical characteristics of this worm can serve as a sort of living history of whether a crab has spawned, potentially giving us a tool to identify how fecundity changes over a female’s life and which crabs are the most productive.”

    In its state advisory role, the Virginia Institute of Marine Science conducts population surveys and provides scientific guidance to inform fisheries management and is continuing to track the proportion of multiparous spawners using the worms as a biomarker. The results from this and related studies will be shared with all partners involved in managing the Bay’s blue crab fishery. The authors note that additional research on the reproductive ecology of female blue crabs may help to better manage this vitally important species.

    Continue Reading

  • Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma

    Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma

    The combination of belantamab mafodotin-blmf (Blenrep), bortezomib (Velcade), and dexamethasone (BVd) produced superior progression-free survival (PFS), sustained overall survival (OS) benefit, and favorable minimal residual disease (MRD) negativity rates vs standard daratumumab (Darzalex) plus bortezomib and dexamethasone (DVd) in patients with multiple myeloma who were refractory to lenalidomide at first relapse, according to findings from a post-hoc analysis of the phase 3 DREAMM-7 trial (NCT04246047).1

    Data presented during the 22nd Annual International Myeloma Society Meeting and Exposition showed that BVD produced clinically meaningful PFS, OS, and PFS2 benefits vs DVd. The median PFS was 35.7 months (95% CI, 17.5-not evaluable [NE]) with BVd (n = 21) vs 13.5 (95% CI, 6.6-26.3) with DVd (n = 27), translating to a HR of 0.39 (95% CI, 0.17-0.88). The 24-month PFS rates were 67% (95% CI, 41%-84%) and 35% (95% CI, 17%-53%) in these respective arms.

    Furthermore, the median OS was not reached (NR; 95% CI, 35.7%-NE) with BVd vs 35.4 months (95% CI, 24.4-NE) with DVd (HR, 0.64; 95% CI, 0.26-1.59). The 24- and 36-month OS rates in the BVd arm were 79% (95% CI, 53%-92%) and 74% (95% CI, 48%-88%), respectively. In the DVd arm, these respective rates were 77% (95% CI, 55%-89%) and 50% (95% CI, 28%-68%).

    “Treatment benefits with BVd were maintained after subsequent [treatment with] antimyeloma therapies…[and] the safety and tolerability of the BVd regimen were consistent with the primary analysis,” presenting author María-Victoria Mateos, MD, PhD, stated in a presentation of the data. “These results support the consideration of BVd as a new potential standard of care for lenalidomide-refractory patients with relapsed/refractory multiple myeloma and only 1 prior line of therapy, addressing a critical unmet need in this [patient] population.”

    Mateos is a consultant physician and associate professor of medicine in the Hematology Department at the University of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC) in Spain.

    What Clinical Need Does BVd Address in Lenalidomide-Refractory Multiple Myeloma?

    In November 2024, the FDA accepted a biologics license application seeking the approval of BVd for the treatment of patients with multiple myeloma who have received at least 1 prior line of therapy, partly based on data from DREAMM-7.2

    Prior findings from DREAMM-7, which were published in the New England Journal of Medicine, showed that at a median follow-up of 28.2 months (range, 0.1-40.0), the median PFS with BVd (n = 243) was 36.6 months (95% CI, 28.4-NR) vs 13.4 months (95% CI, 11.1-17.5) with DVd (n = 251; HR, 0.41; 95% CI, 0.31-0.53; P < .001).3

    Investigators conducted a post hoc analysis to examine outcomes in the subgroup of patients from DREAMM-7 who were lenalidomide-refractory at first relapse.1

    What Was the Design of the DREAMM-7 Trial Subgroup Analysis?

    The randomized, open-label DREAMM-7 trial enrolled 494 patients 18 years of age and older with relapsed/refractory multiple myeloma who had received at least 1 prior line of therapy. Prior treatment with an anti-BCMA therapy or refractoriness to anti-CD38 therapy was not permitted, nor was disease that was refractory or intolerant to bortezomib.1,3,4

    Eligible patients were randomly assigned 1:1 to receive the following regimens:

    • 2.5 mg/kg of intravenous (IV) belantamab mafodotin every 3 weeks in combination with bortezomib and dexamethasone for 8 cycles; belantamab mafodotin monotherapy in cycle 9 and beyond
    • 16 mg/kg of IV belantamab mafodotin weekly during cycles 1 to 3 and every 3 weeks in cycles 4 to 8 in combination with bortezomib and dexamethasone for 8 cycles; daratumumab monotherapy in cycle 9 and beyond

    Treatment continued until disease progression, death, unacceptable toxicity, withdrawal of consent, or study conclusion.

    The trial’s primary end point was PFS. Secondary end points included OS, duration of response (DOR), and MRD negativity.3 Post hoc analyses of PFS, OS, PFS2, overall response rate (ORR), MRD, and DOR were performed in patients who had received at least 1 prior line of therapy and were refractory to lenalidomide.1

    Were Patient Characteristics Balanced Between the BVd and DVd Arms at Baseline in the DREAMM-7 Post Hoc Analysis?

    The data cutoff for the current analysis was October 7, 2024. Baseline characteristics were generally balanced across arms. The median age was 65.0 years (range, 34-86) in the BVd arm and 67.0 years (range, 45-81) in the DVd arm. Most patients in both arms were male (73% in BVd arm; 74% in DVd arm), were White (100%; 78%), had standard-risk cytogenetics (73%; 70%), and did not display extramedullary disease (91%; 96%). At screening, 50% vs 37% of patients in the BVd and DVd arms, respectively, had R-ISS stage I disease; 45% vs 59% of patients had stage II disease; and 5% vs 4% of patients had stage III disease.

    Seven and 13 patients from the BVd and DVd arms, respectively, went on to receive subsequent antimyeloma therapy. This included:

    • Steroids: 29% vs 37%
    • Immunomodulators: 29% vs 33%
    • Proteasome inhibitors: 19% vs 30%
    • Chemotherapy: 19% vs 15%
    • Monoclonal antibodies: 24% vs 7%
    • Antibody-drug conjugates: 5% vs 11%
    • Bispecific antibodies: 0% vs 7%
    • Engineered T-cell or natural killer–cell therapy: 0% vs 4%
    • Other therapy: 5% vs 4%

    Of note, information on subsequent therapy was missing for 10% of patients in the BVd arm.

    What Were the PFS2, Response, and MRD Negativity Rates with BVd vs DVd?

    PFS2 benefit was maintained with BVd followed subsequent treatment with antimyeloma therapies. The median PFS2 with BVd was NR (95% CI, 29.0-NE) vs 29.3 (95% CI, 13.8-NE) with DVd (estimated HR, 0.66; 95% CI, 0.27-1.59).

    BVd also led to high rates of MRD negativity and deep, durable responses in this patient population. The respective response rates for BVd and DVd were as follows:

    • BVd: ORR, 95.2% (95% CI, 76.2%-99.9%)
      • 14.3% stringent complete response (sCR; n = 3); 42.9% CR (n = 9); 23.8% very good partial response (VGPR; n = 5); 14.3% PR (n = 3)
    • DVd: ORR, 81.5% (95% CI, 61.9%-93.7%)
      • 11.1% sCR (n = 3); 14.8% CR (n = 4); 40.7% VGPR (n = 11); 14.8% PR (n = 4)

    The median DOR with BVd was NR (95% CI, 16.2-NE) vs 13.1 months (95% CI, 7.0-NE) with DVd. The 24-month DOR rates were 65% (95% CI, 38.0%-82.0%) and 36% (95% CI, 17.0%-56.0%) with these respective regimens.

    A CR or higher and MRD negativity were achieved by 38.1% (95% CI, 18.1%-61.6%) of patients in the BVd arm vs 7.4% (95% CI, 0.9%-24.3%) of patients in the DVd arm; the MRD negativity rates in patients with a CR or greater were 67% and 29%, respectively. A VGPR or greater and MRD negativity were achieved by 57.1% (95% CI, 34.0%-78.2%) of patients in the BVd arm and 22.2% (95% CI, 8.6%-42.3%) of patients in the DVd arm; respective MRD negativity rates among those patients with a VGPR or greater were accordingly 71% and 33%.

    Was the Safety Profile of BVd Consistent with Prior Findings in This Patient Population?

    No new safety concerns were reported with BVd or DVd in the post hoc analysis. All patients across both arms experienced adverse effects (AEs) of any grade, 100% of which were related to any study treatment. Grade 3 or 4 AEs were reported in 100% of patients in the BVd arm and 78% of those in the DVd arm; of these, 100% and 70% were deemed treatment related, respectively.

    AEs led to permanent discontinuation of any study drug in 29% and 15% of patients in the BVd and DVd arms, respectively. All 29% of patients in the BVd arm who discontinued treatment did so due to AEs related to the study drug, vs 11% of those in the DVd arm. Patients also experienced AEs leading to dose reduction (71% vs 56%) and dose interruption or delay (95% vs 78%).

    Any-grade serious AEs (AEs) were reported in 62% and 41% of patients in the BVd vs DVd arms, respectively; of these, 29% and 15% were related to the study drug. Fatal serious AEs occurred in 5% of patients in the BVd arm and 7% of patients in the DVd arm; none of these effects were deemed related to study treatment.

    References

    1. Hungria V, Robak P, Hus M, et al. Outcomes in second-line lenalidomide-refractory patients in the phase 3 DREAMM-7 study of belantamab mafodotin, bortezomib (V), and dexamethasone (d) vs daratumumab-Vd in RRMM. Presented at: 22nd Annual International Myeloma Society Meeting and Exposition; September 17-20, 2025; Toronto, Canada. Abstract PA-494.
    2. Blenrep combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma. News release. GSK. November 25, 2024. Accessed September 19, 2025. https://www.gsk.com/en-gb/media/press-releases/blenrep-combinations-accepted-for-review-by-the-us-fda-for-the-treatment-of-relapsedrefractory-multiple-myeloma/
    3. Hungria V, Robak P, Hus M, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(5):393-407. doi:10.1056/NEJMoa2405090
    4. Evaluation of efficacy and safety of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in participants with relapsed/​refractory multiple myeloma (DREAMM 7). ClinicalTrials.gov. Updated October 24, 2025. Accessed September 19, 2025. https://clinicaltrials.gov/study/NCT04246047

    Continue Reading

  • Intel Hits 38-year High, TikTok US-China Deal, Hongkong Land Divests, Centurion REIT and AvePoint

    Intel Hits 38-year High, TikTok US-China Deal, Hongkong Land Divests, Centurion REIT and AvePoint

    Welcome to this week’s edition of top stock market highlights.

    This week delivered significant developments across multiple sectors as Intel posted its best trading day in nearly four decades following Nvidia’s US$5 billion investment, whilst US and Chinese negotiators advanced towards a resolution on TikTok’s American operations.

    In Singapore, the IPO market remained active with Centurion Accommodation REIT’s S$771 million listing and AvePoint’s secondary listing by introduction, as Hongkong Land continued its strategic transformation with the S$739 million divestment of MCL Land to Malaysia’s Sunway Group.

    Intel shares posted their best trading day since October 1987, surging 22.8% to US$30.57 on 18 September following Nvidia’s announcement of a US$5 billion investment in the troubled chipmaker.

    The investment, made at US$23.28 per share, forms part of a strategic collaboration to co-develop data centre and PC chips.

    The partnership represents a significant vote of confidence in Intel’s turnaround efforts, with Nvidia joining Softbank and the US government as major investors.

    The US government had previously invested US$8.9 billion for a 10% stake in August 2025, a position now valued at US$13.2 billion following the share price surge.

    Under the agreement, Intel will manufacture x86 central processing units for Nvidia’s AI infrastructure platforms and develop x86 system-on-chips incorporating Nvidia’s RTX graphics processing units for personal computers.

    White House deputy press secretary Kush Desai characterised the partnership as “a major milestone for American high-tech manufacturing,” underscoring the strategic importance of strengthening domestic semiconductor capabilities.

    Nvidia shares also responded positively, closing 3.54% higher on the day.

    Major progress emerged in the long-running saga over TikTok’s US operations as negotiators from Washington and Beijing finalised a framework agreement that could reshape the social media giant’s American presence.

    The deal, discussed during trade talks in Madrid this week, would create a new US entity with American investors holding approximately 80% and Chinese shareholders retaining the remaining 20%.

    The investor consortium includes technology giants Oracle, which fell 1.59% on the news, alongside private equity firm Silver Lake and venture capital firm Andreessen Horowitz.

    Existing ByteDance investors including Susquehanna International, KKR and General Atlantic would also participate in the new ownership structure.

    Under the proposed framework, existing US users would transition to a new app that TikTok has already built and is testing.

    Oracle would handle user data at its Texas facilities, whilst TikTok engineers would recreate content-recommendation algorithms using technology licensed from parent company ByteDance.

    The new entity would feature an American-dominated board with one member designated by the US government.

    President Trump announced the breakthrough, stating he would speak with Chinese President Xi Jinping on Friday to finalise details.

    The executive order extending the TikTok ban has been pushed back to 16 December, providing time for the transaction to complete.

    Wang Jingtao, deputy director of China’s top cyberspace regulator, confirmed that “both sides have reached a basic consensus on resolving the TikTok issue,” signalling Beijing’s openness to licensing TikTok’s algorithm and intellectual property rights for the US operation.

    Hongkong Land Holdings announced a transformative portfolio restructuring with the divestment of its MCL Land residential development business to Sunway Group for S$739 million (US$579 million).

    The transaction, involving Sunway Labuan Investment Ltd, represents a key milestone in Hongkong Land’s strategic pivot towards ultra-premium integrated commercial properties.

    The sale encompasses MCL Land’s entire Singapore and Malaysia residential development operations, including six residential developments currently under construction and the Wangsa Walk Mall in Kuala Lumpur.

    This brings Hongkong Land’s total capital recycled since 2024 to US$2 billion, achieving 50% of the company’s target of at least US$4 billion by the end of 2027.

    The proceeds will be utilised to reduce net debt and strengthen the balance sheet, with an additional US$150 million allocated to expand the share buyback programme.

    Chief Executive Michael Smith emphasised that the transaction advances the company’s 2035 strategic vision to focus on developing and managing ultra-premium integrated commercial properties in Asian gateway cities.

    MCL Land, with its 60-year heritage, has completed 42 developments across Singapore and seven in Malaysia since 1992.

    The transaction ensures continuity for MCL Land’s operations and employees, who will remain with the business under Sunway’s ownership.

    Singapore’s REIT market welcomed its first pure-play purpose-built living portfolio as Centurion Accommodation REIT prepared for its 25 September listing.

    The REIT, trading under ticker CMWU, marks the second-largest Mainboard listing this year with an IPO targeting S$771.0 million.

    The public offer of 13.2 million units at S$0.88 each opened on 18 September and closes on 23 September.

    The REIT’s portfolio comprises 15 assets valued at S$2.2 billion, including five purpose-built workers’ accommodation assets in Singapore, eight purpose-built student accommodation assets in the UK, and one in Australia.

    CEO Tony Bin highlighted favourable demand dynamics, noting that Singapore’s approximately 400,000 to 500,000 foreign workers face just 124,700 permanent PBWA beds.

    Rental rates have surged from S$250 per bed in 2019 to approximately S$550 presently, with occupancy remaining robust at 96.9%.

    The REIT has projected attractive distribution yields of 7.47% for FY2026 and 8.11% for FY2027, with gross revenue expected to reach S$209.1 million in FY2026 and S$218.2 million in FY2027.

    Technology company AvePoint marked a significant milestone for Singapore Exchange with its secondary listing by way of introduction, offering local investors direct access to a US growth story without the company raising new capital.

    The Microsoft partner, which provides data management and governance solutions, chose Singapore to expand its investor base and tap into Asian growth opportunities.

    AvePoint’s revenue trajectory demonstrates strong momentum, growing from US$232.3 million in 2022 to US$330.5 million in 2024, representing a 42% increase over the period.

    For the six months ended 30 June 2025, revenue reached US$195.1 million, up 27.9% year on year.

    The secondary listing strengthens Singapore’s position as a technology hub whilst providing local investors with rare exposure to a profitable SaaS company.

    Trading in Singapore dollars simplifies portfolio management for local investors whilst signalling SGX’s evolution beyond its traditional dividend-heavy offerings.

    This listing by introduction allows AvePoint’s existing shares to trade on SGX without diluting current shareholders or raising new capital, demonstrating an alternative path for international companies seeking Asian market presence whilst maintaining their primary US listing.

    Attention Growth Investors: Our latest report, “The Rise of Titans,” gives you a front-row seat on the 7 most influential US stocks today. If you’re passionate about tech and growth, you can’t go wrong with our research. Downloading this FREE report could be the most strategic move you make this year. Click here to get started now.

    Follow us on Facebook, Instagram and Telegram for the latest investing news and analyses!

    The post Top Stock Market Highlights: Intel Hits 38-year High, TikTok US-China Deal, Hongkong Land Divests, Centurion REIT and AvePoint appeared first on The Smart Investor.


    Continue Reading

  • ‘The Lost Bus’ review: 2018 Camp fire becomes McConaughey disaster movie

    ‘The Lost Bus’ review: 2018 Camp fire becomes McConaughey disaster movie

    Disasters are real — also, these days, frighteningly common, be they epic confluences of nature and negligence or the murderous and preventable kind. And when it comes to disaster movies, it’s hard to know what the acceptable level of exploitation is.

    Of course, director Paul Greengrass could never be confused with the unseriousness of producer Irwin Allen (“The Towering Inferno”) or filmmaker Roland Emmerich (“The Day After Tomorrow”), ringmasters who preferred heaping helpings of A-listers on slick, expensive calamities. Rather, when Greengrass, coming from documentaries, tackles dark days of mass casualty, they tend to be true stories like “United 93” and “Bloody Sunday.” His stripped-down, jagged style, absent marquee names and focused on such issues as terrorism and community, brings intelligent urgency to the unfathomable.

    With his new film “The Lost Bus,” however, starring Matthew McConaughey and America Ferrera, about the real-life effort to save a busload of schoolchildren from the 2018 Camp fire, a wildfire that would destroy most of Paradise, Calif., Greengrass is trying to merge the two sensibilities. This time he mixes star heroism with you-are-there spectacle and the results can be galvanizing if awkwardly framed.

    “The Lost Bus” is not as potent as Greengrass’ “Captain Phillips,” in which Tom Hanks anchored a re-created reality no less pulse-pounding than any action blockbuster. Instead the director seems to be in a programmatic mode. There are scenes of nerve-jangling terror that weld you to your seat, but they’re sandwiched in between a lot that feels very much sculpted for three-act character arc effect by Greengrass and co-writer Brad Ingelsby.

    McConaughey plays Paradise bus driver Kevin McKay, whose life is almost comically scripted to come off as especially challenged before one lick of flame gets near it: strapped for cash, dying dog, recently dead father (no love lost), sullen teenage son (love lost), ex-wife (also unhappy) and a memory-ailing mother. But on the afternoon of Nov. 18 as the fires reach eastern Paradise, Kevin’s is the only bus that can meet a request from his dispatcher (Ashlie Atkinson): Pick up stranded elementary schoolkids and evacuate them to safety.

    A failed dad feeling the weight of sudden responsibility, Kevin corrals as co-chaperone a schoolteacher (America Ferrera). Though Mary is a mother eager to get to her own child, she’s willing to help. The occasional cut to Yul Vazquez as the fire chief spearheading rescue efforts, however, is this movie’s barometer of increasingly bad news. As smoke quickly darkens the day and the unstoppable, town-hopping fire hems in the bus, cutting off routes, the journey takes a dystopian turn, raising the stakes and alarm levels to unimaginable heights. (Eaton and Palisades survivors, fair warning — you were never going to watch this anyway.)

    McConaughey is solid casting, his unshowy working-class fortitude slightly tinged with fear. In his and Ferrera’s sturdy presence and in the serrated frenzy of Greengrass’ editing style, a shorter, tighter “The Lost Bus” would still hold plenty of dread and dramatic resilience. The fire sequences alone, captured in the hellish fuzz of Pål Ulvik Rokseth’s cinematography, are pinnacles of this practical-meets-digital-effects discipline. But Kevin’s dippy redemption arc, doled out midperil in tortured glances and forced dialogue, drags us out of the intensity.

    It’s also odd that the activist-minded Greengrass didn’t do more with so corporate a villain: legally responsible utility PG&E, represented in the movie by an ineffectual suit who is briefly yelled at. Forget that redemption story — Greengrass could have leaned even more into those action tropes and, as a final touch, had McConaughey punch PG&E in the jaw.

    ‘The Lost Bus’

    Rated: R, for language

    Running time: 2 hours, 9 minutes

    Playing: In limited release Friday, Sept. 19; on Apple TV+ on Oct. 3

    Continue Reading

  • The Sting, Way We Were, President’s Men

    The Sting, Way We Were, President’s Men

    From ‘Barefoot in the Park’ to ‘All the President’s Men’, the actor and founder of the Sundance Institute built his legend over decades onscreen and off.

    Throughout his six decades in entertainment, Robert Redford reached the status of Hollywood legend with films like Butch Cassidy and the Sundance Kid, All the President’s Men and Out of Africa. He seemingly tackled every genre, from comedy to romance to western to thrillers to, yes, even superhero films.

    Redford died on Tuesday at the age of 89. Below, The Hollywood Reporter has compiled some of his notable onscreen (and behind-the-camera) offerings.


    Continue Reading

  • The Role of Exxon Mobil Corporation (XOM) in a Diversified Dividend Stock Portfolio

    The Role of Exxon Mobil Corporation (XOM) in a Diversified Dividend Stock Portfolio

    Exxon Mobil Corporation (NYSE:XOM) is included among the Best Stocks for a Dividend Stock Portfolio.

    The Role of Exxon Mobil Corporation (XOM) in a Diversified Dividend Stock Portfolio

    Exxon Mobil Corporation (NYSE:XOM) stands as a global powerhouse in liquefied natural gas (LNG), with stakes in multiple projects worldwide that collectively produce around 23 million tons annually. Its portfolio includes major interests in Gorgon LNG, Papua New Guinea LNG, and several LNG facilities in Qatar.

    LNG is one of the company’s four core strategic priorities through 2027, and Exxon Mobil Corporation (NYSE:XOM) is actively expanding in this area. Among its largest undertakings is the Golden Pass LNG project in the US, a more than $10 billion joint venture with QatarEnergy that is expected to begin exports by late 2025, with capacity for about 18 million tons per year.

    Exxon Mobil Corporation (NYSE:XOM) is also partnering with QatarEnergy, Shell, TotalEnergies, and others on the massive North Field expansion in Qatar. This two-phase project will add six LNG trains, increasing total capacity from 77 million tons to 126 million tons annually by 2027, with the first phase carrying an estimated $30 billion price tag.

    With these initiatives, Exxon Mobil Corporation (NYSE:XOM) is positioning itself to nearly double its LNG business to around 40 million tons per year by 2030, reinforcing its leadership in the global energy market. Moreover, the company has been rewarding shareholders with growing dividends for the past 42 years. It currently pays a quarterly dividend of $0.99 per share and has a dividend yield of 3.47%, as of September 18.

    While we acknowledge the potential of XOM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 13 Best Consistent Dividend Stocks to Buy Now and 15 Best Performing Dividend Stocks So Far in 2025.

    Disclosure: None.

    Continue Reading

  • Strictly Come Dancing 2025 launch show first look images and special guest performer revealed

    Strictly Come Dancing 2025 launch show first look images and special guest performer revealed

    Published: 12:08 am, 20 September 2025

    (Image: BBC/Guy Levy)

    Strictly Come Dancing is back, making the autumn and winter months a whole lot more fab-u-lous!

    The multi-award-winning entertainment show, produced by BBC Studios, returns on Saturday 20 September at 6.40pm on BBC One and BBC iPlayer and new first look pictures offer a sneak peek at what’s in store!

    A collage of Strictly pros Dianne and Kai dancing together. On the left, they strike a pose as they begin to dance. On the right, Kai lifts Dianne to sit on his shoulder as she holds the glitterball trophy above her head.
    The Strictly professional dancers and judges perform a dance routine involving a block of large white stairs, backlit by purple beams of light as the audience watch on
    The Strictly professionl dancers move energetically across the dance floor in formation, lit by bright white lights

    The launch show starts with a bang as the entire Strictly family hit the dance floor for an epic opening performance.

    Two new professionals arrive in style with a sizzling poolside routine, Jessie J provides music and 2024 Strictly champions Chris McCausland and Dianne Buswell return for one last dance together.

    Strictly professional dancers Luba Mushtuk and Gorka Marquez perform together in front of Jessie J, who stands on a podium singing in a red suit with her arms wide open
    Dianne Buswell and Chris McCausland dancing - they are linked by a single hand as they stretch apart mid routine in an elegant ballroom dance

    The celebrities waltzing onto our screens this year are Alex Kingston, Balvinder Sopal, Chris Robshaw, Dani Dyer, Ellie Goldstein, George Clarke, Harry Aikines-Aryeetey AKA Nitro, Jimmy Floyd Hasselbaink, Karen Carney, La Voix, Lewis Cope, Ross King, Stefan Dennis, Thomas Skinner and Vicky Pattison.

    The Strictly Come Dancing 2025 celebrities stand on the ballroom floor together smiling and clapping

    Our hosts Tess Daly and Claudia Winkleman will welcome them onto the Strictly dancefloor, as they make their dancing debut and discover which Professional Dancer they will be paired with.

    Watching their every move will be our Strictly Judges – Craig Revel Horwood, Motsi Mabuse, Anton Du Beke and Head Judge Shirley Ballas.

    Left: Strictly judges Craig, Motsi, Shirley and Anton sit behind a large judges' desk. Right: Hosts Claudia and Tess stand together smiling on the ballroom floor.

    Our dazzling professional dancers for the new series are: Aljaž Škorjanec, Amy Dowden MBE, Carlos Gu, Dianne Buswell, Gorka Marquez, Johannes Radebe, Jowita Przystal, Kai Widdrington, Karen Hauer, Katya Jones, Lauren Oakley, Luba Mushtuk, Michelle Tsiakkas, Nadiya Bychkova, Nancy Xu, Neil Jones, Nikita Kuzmin and Vito Coppola. Joining them for the first time will be our two brand new Pros, Alexis Warr and Julian Caillon.

    The Strictly professional dances cross their legs as they stride across the dance floor

    Strictly Come Dancing is a BBC Studios Entertainment production for BBC One and BBC iPlayer and was commissioned by Kalpna Patel-Knight, Head of Entertainment at the BBC. The Executive Producer is Sarah James, the Series Editors are Nicola Fitzgerald and Jack Gledhill. The Commissioning Editor for the BBC is Jo Wallace.

    GK

    Follow for more

    Continue Reading

  • ‘Female models were rightly paid more than us. I wanted to even things up’

    ‘Female models were rightly paid more than us. I wanted to even things up’

    BBC David Gandy is wearing a black t-shirt and has a serious expression on his faceBBC

    David Gandy

    David Gandy is relaxed. The Essex-born supermodel is sitting in his light-filled kitchen, sipping a glass of water and reflecting on his almost 25-year career.

    At 45, Gandy’s striking dark brown hair, sharp cheekbones and piercing blue eyes have been at the centre of some of fashion’s most iconic campaigns of the last two decades, and he is one of the few male models to become a household name.

    “I always say that I was inspired by the female supermodels,” Gandy says, name-checking Cindy Crawford, Kate Moss and Naomi Campbell. “You don’t even need to say the surnames.

    “It’s not like I’ve ever got to that status,” he laughs.

    ‘We’re now seeing campaigns where the model doesn’t even exist’

    It was Gandy’s contract with Dolce & Gabbana that catapulted his career, with the model fronting a campaign for the brand’s Light Blue fragrance line – to this day, arguably his most notable work.

    It began with an advert in which Gandy stands at the helm of a boat bobbing about a cove near Capri, Italy, wearing only a pair of white trunks. His hair is slicked back, as he leans into an embrace with model Marija Vujović. Gandy remained the face of the brand for an impressive 18 years.

    He tells me the Light Blue campaign gave him a platform to approach the level of his female counterparts. “They were paid so much more than us – rightly so. I just wanted to even things up a little bit,” he says with a chuckle.

    Alamy 2010s UK Dolce & Gabbana Magazine Advert showing Divid Gandy in white swimming trunksAlamy

    2010s UK Dolce & Gabbana Magazine Advert

    Gandy spoke to BBC News ahead of London Fashion Week, which continues this weekend, and was keen to discuss what he sees as an existential threat to the fashion industry from artificial intelligence (AI).

    It comes as more than 2,000 professional models, including Gandy, Twiggy and Yasmin Le Bon, call on the government to protect people’s rights when generative AI can be used to create human-like images in a matter of seconds.

    “We’re now seeing campaigns created by the likes of Guess and other brands where the model doesn’t exist at all,” Gandy says. “Whether that is AI learning – they call it scraping – little bits of imagery from different models and different people, and creating that into an image, is one of the grey areas and the problems.”

    Seraphinne Vallora AI generated image of a woman with long brown hair wearing a white maxi dress standing in front of waterSeraphinne Vallora

    An AI-generated model created for Guess’s summer collection

    Gandy fears that without further regulation, the use of AI models could irreparably damage the industry.

    “Britain produces some of the greatest models,” he says, “and we want to keep that tradition going.”

    It’s not only the impact on models Gandy is concerned about, but also on those involved in the making of fashion imagery – including photographers.

    “The idea that you’re taking away this artistry from people,” he explains. “The hairdressers, the make-up artists, lots of assistants, even the location itself. You’re making that whole element redundant.”

    ‘I’ve always split my private life and my business life’

    As the father of two young daughters, Gandy says he worries too about the effect of AI-generated imagery on mental health, particularly among young people.

    “Looking at something that isn’t even real – where the person doesn’t exist – we don’t yet know the impact of that yet,” he says.

    Gandy acknowledges that the fashion industry will inevitably need to embrace AI in some ways, but stresses, “There has to be regulation”.

    For many, supermodel status can mean your personal life is as well-known as your work in fashion. But from his home near London’s Richmond Park – which he shares with his partner Stephanie Mendoros, his daughters, and their rescue dog, Dora – Gandy tells me he guards his privacy fiercely. On our visit, he is careful to shield the pictures of his family dotted around the house.

    “I’ve always split my private life and my business life,” he says. “They’re two separate things. No one knows what my children look like; there are no images of them online. And I won’t be posting what I had for breakfast!”

    Conversation swiftly turns to his garden. “I think you get to an age, I’m not sure if it’s about 40 years old, but some men become obsessed with their lawn,” he says, something he jokingly admits hasn’t benefited from having a bouncy castle on it all summer.

    He tells me his daughters like to dress him up, too. “They’ve put hair bands on me that have bunny ears and bear ears, and I’ve forgotten that I’ve been wearing them,” he recalls, “So then I’ve gone shopping with them on.”

    “I’ve come back and my partner has said to me, ‘You know you’ve got bunny ears on?’”

    Gandy shakes his head, laughing.

    Getty Images Stephanie Mendoros and David Gandy attend The Mayfair Gallery Hop to launch Brown's London Art Weekend at Messums Gallery on July 1, 2016 in LondonGetty Images

    David and long-term partner Stephanie Mendoros have two daughters together

    Some of his children’s friends now recognise him from adverts, he tells me, but despite being such a well-known face, Gandy says he doesn’t often get recognised in the street.

    “I’ve had people standing in front of the big posters and telling me, ‘I recognise you from somewhere’, when the poster is behind them,” he laughs gently, adding that he never worries about setting anyone straight.

    “I always say I have quite a nice level of fame,” Gandy says. “Ninety-nine per cent of people are very polite when they come up to me and have a conversation.”

    A government spokesperson said:

    “Fast-moving technologies like AI bring huge opportunities and also complex challenges. We know some individuals are concerned about their ability to protect their likeness.

    “UK law already offers some protection for aspects of a person’s identity, and we continue to seek views on how they are working and if any changes may be needed.”

    Guess was approached for comment.

    Continue Reading

  • Digital Psychological Intervention for Inflammatory Rheumatic Diseases: A Pilot Randomized Clinical Trial

    Digital Psychological Intervention for Inflammatory Rheumatic Diseases: A Pilot Randomized Clinical Trial

    1. In patients with inflammatory rheumatic diseases (IRD), digital psychological intervention was associated with improved psychological outcomes and quality of life at 3 months of follow-up.

    Evidence Rating Level: 1 (Excellent) 

    Inflammatory rheumatic diseases (IRD) are a series of diseases, including rheumatoid arthritis (RA) and psoriatic arthritis (PsA), which are becoming more prevalent. Women are disproportionately affected, specifically more prone to systemic lupus erythematosus (SLE). Although these conditions are characterized as physical, many patients also experience significant psychological challenges, such as anxiety and depression. This eventually contributes to a feedback loop, further intensifying physical symptoms and worsening quality of life. Previous studies have demonstrated the effectiveness of cognitive behavioural therapy (CBT) along with other therapy treatments in managing psychological distress in these patients. However, there have been shortages of mental health treatment available for these patients. This randomized controlled trial sought to address these gaps by assessing the effectiveness of a web-based CBT intervention at reducing psychological distress in patients with IRD. The online questionnaires were sent out at baseline, 6 weeks, and 12 weeks. 102 participants (mean [SD] age, 47.2 [12.9] years; 92 [90.2%] female). Change in psychological distress levels was assessed using the Hospital Anxiety and Depression Scale (HADS-D), and quality of life was assessed using the Assessment of Quality of Life-8 Dimensions (AQoL-8D). There was a significantly greater reduction in psychological distress (least-squares mean difference, -3.60 [1.07]; 95% CI, -5.73 to -1.47; P<.001; Cohen d=-0.71) and improvement in quality of life (least-squares mean [SE] difference, 0.04 [0.02]; 95% CI, 0.00-0.09; P=.047; Cohen d=0.49) in the intervention group compared to the control group at follow up. Overall, this study found that the use of online therapy was associated with a reduction in psychological distress and an improvement in quality of life.  

    Click to read this study in JAMA Network Open

    Image: PD

    ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

    Continue Reading

  • Queen Elizabeth statue will show ‘grandeur and dignity,’ sculptor says

    Queen Elizabeth statue will show ‘grandeur and dignity,’ sculptor says

    PA Media A mock-up of St James's Park with a large statue of Queen Elizabeth II on horseback high above ground. The statue sits on a plinth in between two rows of tall trees. People are milling about around it and on the pavement off to the right. It is daytime.PA Media

    An artist’s impression of the design for the memorial indicated how a statue of the queen might look

    The sculptor chosen to create a statue of Queen Elizabeth II for her national memorial has said he wants to capture the “grandeur and dignity” of Britain’s longest-reigning monarch.

    Martin Jennings, who has previously depicted King Charles III and the Queen Mother, said he was “elated” to be chosen to portray the late queen.

    “She was loved and admired across the globe for her steadfast devotion to duty, borne with grace, decency and restraint.”

    The statue will be of the memorial in central London’s St James’s Park, with the final design to be revealed in 2026.

    The British sculptor told the PA news agency that he did not have a “defined idea” of how the statue would look yet, and that he would want the Royal Family’s approval.

    But he said he hoped to convey the appropriate “grandeur and dignity” and that “a certain amount of stillness” would be beneficial.

    Mr Jennings added that people had “strong feelings about the queen”.

    “I will be going through a period of listening to not only what invested organisations and individuals want of it, but taking the temperature of how the populace at large might want to see this representation.”

    PA Media Martin Jennings at Marlborough Gate, St James's Park. It is sunny outside and he wears a beige linen suit and is smiling with his hands held casually behind his backPA Media

    Martin Jennings said he would like royal approval of his design

    A section of St James’s Park visible from Buckingham Palace will be re-landscaped for the national memorial, with a budget previously said to be between £23m and £46m.

    The anti-monarchy campaign group Republic has called for the Royal Family to pay for the memorial rather than the government.

    “They can pay for their own statue,” the group’s chief executive Graham Smith said.

    The winning design for the memorial, chosen from a shortlist of five concepts, will feature a bridge with a balustrade made of glass, inspired by the shape of the late queen’s wedding tiara.

    There will also be a statue of her and Prince Philip, to whom she was married for 73 years until his death in 2021, a Prince Philip Gate and new gardens.

    The final designs will be put to the King and the prime minister next year.

    Continue Reading